Millennium Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-273,520
| Closed | -$47.1M | – | 7798 |
|
|
2021
Q3 | $47.1M | Buy |
273,520
+261,193
| +2,119% | +$34.2M | 0.03% | 664 |
|
|
2021
Q2 | $1.55M | Buy |
12,327
+10,628
| +626% | +$1.34M | ﹤0.01% | 4241 |
|
|
2021
Q1 | $230K | Buy |
+1,699
| New | +$219K | ﹤0.01% | 5414 |
|
|
2020
Q4 | – | Sell |
-7,446
| Closed | -$873K | – | 5756 |
|
|
2020
Q3 | $838 | Sell |
7,446
-184,301
| -96% | -$18.3M | ﹤0.01% | 3252 |
|
|
2020
Q2 | $18.3M | Sell |
191,747
-52,978
| -22% | -$5.11M | 0.03% | 792 |
|
|
2020
Q1 | $22M | Buy |
244,725
+236,287
| +2,800% | +$18.4M | 0.05% | 409 |
|
|
2019
Q4 | $447K | Sell |
8,438
-33,174
| -80% | -$1.51M | ﹤0.01% | 3455 |
|
|
2019
Q3 | $1.64M | Sell |
41,612
-52,091
| -56% | -$2.26M | ﹤0.01% | 2568 |
|
|
2019
Q2 | $3.85M | Buy |
93,703
+35,319
| +60% | +$1.46M | 0.01% | 1970 |
|
|
2019
Q1 | $2.72M | Buy |
+58,384
| New | +$2.56M | ﹤0.01% | 2204 |
|
|
2018
Q4 | – | Sell |
-7,570
| Closed | -$433K | – | 4358 |
|
|
2018
Q3 | $433K | Buy |
+7,570
| New | +$372K | ﹤0.01% | 3313 |
|
|
2018
Q2 | – | Sell |
-98,050
| Closed | -$3.57M | – | 4332 |
|
|
2018
Q1 | $3.83M | Buy |
+98,050
| New | +$4.17M | 0.01% | 1965 |
|
|
2017
Q4 | – | Sell |
-359,304
| Closed | -$13.4M | – | 4197 |
|
|
2017
Q3 | $13.4M | Sell |
359,304
-184,174
| -34% | -$6.39M | 0.02% | 1045 |
|
|
2017
Q2 | $16.5M | Sell |
543,478
-1,372
| -0.3% | -$39.8K | 0.03% | 767 |
|
|
2017
Q1 | $14.4M | Buy |
544,850
+525,239
| +2,678% | +$13.8M | 0.03% | 827 |
|
|
2016
Q4 | $500K | Sell |
19,611
-204,703
| -91% | -$6.49M | ﹤0.01% | 2673 |
|
|
2016
Q3 | $8.12M | Buy |
224,314
+194,314
| +648% | +$6.44M | 0.01% | 1045 |
|
|
2016
Q2 | $1.02M | Buy |
30,000
+5,000
| +20% | +$163K | ﹤0.01% | 2158 |
|
|
2016
Q1 | $660K | Sell |
25,000
-677,177
| -96% | -$19.7M | ﹤0.01% | 2382 |
|
|
2015
Q4 | $34.2M | Buy |
702,177
+553,484
| +372% | +$19.9M | 0.07% | 374 |
|
|
2015
Q3 | $3.7M | Buy |
148,693
+76,828
| +107% | +$2.31M | 0.01% | 1506 |
|
|
2015
Q2 | $2.27M | Buy |
+71,865
| New | +$2.32M | ﹤0.01% | 1833 |
|
|
2014
Q3 | – | Sell |
-23,051
| Closed | -$783K | – | 4112 |
|
|
2014
Q2 | $783K | Buy |
+23,051
| New | +$771K | ﹤0.01% | 2334 |
|
Millennium Management's XLRN Position: Q4 2021 in Review
Millennium Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 273,520 shares — an estimated $47.1M sold.
Millennium Management first reported a position in XLRN in Q2 2014 and held it in 23 quarters. The position peaked at $47.1M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Millennium Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Millennium Management sold 273,520 Acceleron Pharma shares in Q4 2021, an estimated $47.1M.
- Millennium Management first reported a position in Acceleron Pharma in Q2 2014 and held it in 23 quarters.
- Millennium Management's Acceleron Pharma position peaked at $47.1M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Millennium Management's 13F filing for Q4 2021, filed 14 Feb 2022.